MMP14 and neoplasm: The past failures in the clinical trials of MT1-MMP inhibitors are mainly due to off-target-driven side effects but highly MT1-MMP-specific inhibitors have recently been reported from multiple groups so they could be a potential intervention that could conquer the MT1-MMP-driven tumor malignancy.